JP2018519361A - 口腔、咽喉及び気道の障害の治療のための配合物 - Google Patents
口腔、咽喉及び気道の障害の治療のための配合物 Download PDFInfo
- Publication number
- JP2018519361A JP2018519361A JP2018516646A JP2018516646A JP2018519361A JP 2018519361 A JP2018519361 A JP 2018519361A JP 2018516646 A JP2018516646 A JP 2018516646A JP 2018516646 A JP2018516646 A JP 2018516646A JP 2018519361 A JP2018519361 A JP 2018519361A
- Authority
- JP
- Japan
- Prior art keywords
- combination
- extract
- extracts
- use according
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 238000011282 treatment Methods 0.000 title claims abstract description 18
- 238000009472 formulation Methods 0.000 title abstract description 14
- 239000000284 extract Substances 0.000 claims abstract description 71
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 25
- 244000294611 Punica granatum Species 0.000 claims abstract description 24
- 235000014360 Punica granatum Nutrition 0.000 claims abstract description 24
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 20
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 18
- 201000009240 nasopharyngitis Diseases 0.000 claims abstract description 17
- 206010022000 influenza Diseases 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 201000007100 Pharyngitis Diseases 0.000 claims abstract description 6
- 206010068319 Oropharyngeal pain Diseases 0.000 claims abstract description 5
- 230000001580 bacterial effect Effects 0.000 claims abstract description 5
- 239000013543 active substance Substances 0.000 claims description 14
- 210000000214 mouth Anatomy 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 11
- 208000036071 Rhinorrhea Diseases 0.000 claims description 8
- 206010039101 Rhinorrhoea Diseases 0.000 claims description 8
- 239000008513 turmeric extract Substances 0.000 claims description 8
- 210000003296 saliva Anatomy 0.000 claims description 7
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 claims description 6
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 claims description 6
- 235000002780 gingerol Nutrition 0.000 claims description 6
- 206010011224 Cough Diseases 0.000 claims description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 5
- 235000013824 polyphenols Nutrition 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 208000000059 Dyspnea Diseases 0.000 claims description 3
- 206010013975 Dyspnoeas Diseases 0.000 claims description 3
- 206010028748 Nasal obstruction Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 230000036760 body temperature Effects 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 230000007170 pathology Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 206010019233 Headaches Diseases 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 206010025482 malaise Diseases 0.000 claims description 2
- 206010041232 sneezing Diseases 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000002676 xenobiotic agent Substances 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 4
- 239000003242 anti bacterial agent Substances 0.000 abstract description 2
- 229940088710 antibiotic agent Drugs 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 14
- 201000010099 disease Diseases 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000003826 tablet Substances 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 102000016943 Muramidase Human genes 0.000 description 7
- 108010014251 Muramidase Proteins 0.000 description 7
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 7
- 229960000274 lysozyme Drugs 0.000 description 7
- 235000010335 lysozyme Nutrition 0.000 description 7
- 239000004325 lysozyme Substances 0.000 description 7
- 210000003800 pharynx Anatomy 0.000 description 7
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 235000003392 Curcuma domestica Nutrition 0.000 description 3
- 229920002079 Ellagic acid Polymers 0.000 description 3
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 244000273928 Zingiber officinale Species 0.000 description 3
- 235000006886 Zingiber officinale Nutrition 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 229960002852 ellagic acid Drugs 0.000 description 3
- 235000004132 ellagic acid Nutrition 0.000 description 3
- 235000008397 ginger Nutrition 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 3
- 230000003232 mucoadhesive effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 235000013976 turmeric Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 235000014375 Curcuma Nutrition 0.000 description 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000020708 ginger extract Nutrition 0.000 description 2
- 229940002508 ginger extract Drugs 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- -1 nother Species 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940109529 pomegranate extract Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229960001462 sodium cyclamate Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229940052016 turmeric extract Drugs 0.000 description 2
- 235000020240 turmeric extract Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 244000187129 Bacopa monnieria Species 0.000 description 1
- 235000015418 Bacopa monnieria Nutrition 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 244000302899 Cassia mimosoides Species 0.000 description 1
- 235000014112 Cassia mimosoides Nutrition 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 208000019736 Cranial nerve disease Diseases 0.000 description 1
- 229930153442 Curcuminoid Natural products 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 244000119298 Emblica officinalis Species 0.000 description 1
- 235000015489 Emblica officinalis Nutrition 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000025467 Gastrointestinal mucosal disease Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010065233 Oral bacterial infection Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 102000011040 TRPV Cation Channels Human genes 0.000 description 1
- 108010062740 TRPV Cation Channels Proteins 0.000 description 1
- 102000003566 TRPV1 Human genes 0.000 description 1
- 101150016206 Trpv1 gene Proteins 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 241000234314 Zingiber Species 0.000 description 1
- 241001247821 Ziziphus Species 0.000 description 1
- 244000158786 Ziziphus joazeiro Species 0.000 description 1
- 235000001329 Ziziphus joazeiro Nutrition 0.000 description 1
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000014826 cranial nerve neuropathy Diseases 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 229920001190 pomegranate ellagitannin Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- LMIBIMUSUFYFJN-RSVYENFWSA-N punicalagin Natural products O[C@@H]1O[C@@H]2COC(=O)c3cc(O)c(O)c(O)c3c4c(O)cc5OC(=O)c6c(c(O)c(O)c7OC(=O)c4c5c67)c8c(O)c(O)c(O)cc8C(=O)O[C@H]2[C@@H]9OC(=O)c%10cc(O)c(O)c(O)c%10c%11c(O)c(O)c(O)cc%11C(=O)O[C@@H]19 LMIBIMUSUFYFJN-RSVYENFWSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
クルクマ・ロンガ抽出物:20mg〜100mg
ピューニカ・グラネイタム抽出物(40%エラグ酸誘導体含有):10mg〜60mg
ジンギベル・オフィキナレ抽出物(35%ギンゲロール含有):2mg〜20mg
クルクマ・ロンガ抽出物:50mg
ピューニカ・グラネイタム抽出物(40%エラグ酸誘導体含有):20mg
ジンギベル・オフィキナレ抽出物(35%ギンゲロール含有):10mg
これらの量は各々±15%の範囲で変動可能である。
クルクマ・ロンガアルコール抽出物(ウコン)又は他の種(other species):50mg
ピューニカ・グラネイタム抽出物40%エラグ酸誘導体:20mg
ジンギベル・オフィキナレ脂溶性抽出物35%ギンゲロール:8mg
キシリトール:430mg
ヒアルロン酸:200mg
グリチルリチン酸アンモニウム:10mg
シクラミン酸ナトリウム:40mg
ポリソルベート80:5mg
クルクマ・ロンガアルコール抽出物(ウコン)又は他の種(other species):50mg
ピューニカ・グラネイタム抽出物40%エラグ酸誘導体:20mg
ジンギベル・オフィキナレ脂溶性抽出物:10mg
アルギン酸ナトリウム塩:200mg
キシリトール:600mg
グリチルリチン酸アンモニウム:10mg
シクラミン酸ナトリウム:40mg
ポリソルベート80:5mg
本研究には多数の患者(1群当たり60人超)が参加した。被験体に任意のサプリメント又は治療についての情報を与え、サプリメントが何であるかを知らせた。生じ得るプラシーボ効果を慎重に説明し、検討した。データを観察期間後に、理想的には十分な証拠が収集された時点で分析した。群間差を認めるのに要する時間も評価標的とみなした。
1.「ヒリヒリした」咽喉痛
2.くしゃみ
3.鼻漏
4.鼻閉塞
5.倦怠感
6.咳
7.発熱
a−エピソードの出現の評価
b−兆候/症状の低減
c−疾患の日数の低減、他の対症療法の使用の低減
d−感冒関連潜在的合併症の制御
e−唾液及びリゾチーム含量の決定
Claims (13)
- 口腔、咽喉及び気道の障害の予防及び/又は治療における使用のためのクルクマ・ロンガ、ピューニカ・グラネイタム及びジンギベル・オフィキナレの抽出物からなる活性物質の組合せであって、該抽出物がそれぞれの重量比6(±2):2(±1):1(±0.5)で存在する、組合せ。
- 口腔、咽喉及び気道の障害の予防及び/又は治療における使用のためのクルクマ・ロンガ、ピューニカ・グラネイタム及びジンギベル・オフィキナレの抽出物を含む活性物質の組合せであって、該抽出物がそれぞれの重量比6(±2):2(±1):1(±0.5)で存在し、
前記抽出物が全体として全投与活性物質の50重量%超を占め、及び/又は、
前記抽出物以外の各々の考え得る活性物質が、前記クルクマ・ロンガ、ピューニカ・グラネイタム及びジンギベル・オフィキナレの抽出物のうち最低のものよりも少なくとも50重量%低い量で存在する、
組合せ。 - 前記クルクマ・ロンガ、ピューニカ・グラネイタム及びジンギベル・オフィキナレの抽出物が全体として全投与活性物質の90重量%超を占める、請求項2に記載の使用のための組合せ。
- 前記クルクマ・ロンガの抽出物がクルクミノイドを20重量%〜30重量%の量で含有し、前記ピューニカ・グラネイタムの抽出物がポリフェノールを60重量%〜95重量%の量で含有し、前記ジンギベル・オフィキナレの抽出物がギンゲロール及びショウガオールを合計して20重量%〜50重量%の量で含有する、請求項1〜3のいずれか一項に記載の使用のための組合せ。
- 20mg〜100mgのクルクマ・ロンガ抽出物と、10mg〜50mgのピューニカ・グラネイタム抽出物と、2mg〜20mgのジンギベル・オフィキナレ抽出物とを含む投与単位用量として配合される、請求項1〜4のいずれか一項に記載の使用のための組合せ。
- 医薬賦形剤が配合される、請求項1〜5のいずれか一項に記載の使用のための組合せ。
- 口腔投与、経口投与又は吸入投与に好適な形態である、請求項1〜6のいずれか一項に記載の使用のための組合せ。
- 前記障害が細菌活性と関連する、請求項1〜7のいずれか一項に記載の使用のための組合せ。
- 前記障害が普通感冒又はインフルエンザの結果として生じる、請求項1〜8のいずれか一項に記載の使用のための組合せ。
- 前記障害が上咽頭炎、鼻咽喉炎、咽喉痛、咳、鼻水、体温上昇、耳及び/又は咽喉の合併症、呼吸困難、気管支炎、肺炎、くしゃみ、鼻漏、鼻閉塞、倦怠感、頭痛並びに関連病態の1つ以上である、請求項1〜9のいずれか一項に記載の使用のための組合せ。
- 前記組合せと唾液との接触により生体異物の溶解を増進するために更に使用される、請求項1〜10のいずれか一項に記載の使用のための組合せ。
- 治療に使用されるための、請求項1〜7のいずれか一項に記載の抽出物の組合せ。
- 請求項1〜7のいずれか一項に記載の抽出物の組合せを含む医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15171354.2 | 2015-06-10 | ||
EP15171354.2A EP3103464A1 (en) | 2015-06-10 | 2015-06-10 | Formulations for the treatment of disorders of the mouth, throat and respiratory tract |
PCT/IB2016/000795 WO2016198943A1 (en) | 2015-06-10 | 2016-06-10 | Formulations for the treatment of disorders of the mouth, throat and respiratory tract |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018519361A true JP2018519361A (ja) | 2018-07-19 |
JP6966998B2 JP6966998B2 (ja) | 2021-11-17 |
Family
ID=53396312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018516646A Active JP6966998B2 (ja) | 2015-06-10 | 2016-06-10 | 口腔、咽喉及び気道の障害の治療のための配合物 |
Country Status (14)
Country | Link |
---|---|
US (1) | US10758587B2 (ja) |
EP (2) | EP3103464A1 (ja) |
JP (1) | JP6966998B2 (ja) |
KR (1) | KR20180030970A (ja) |
CN (1) | CN108040468B (ja) |
AU (1) | AU2016276145B2 (ja) |
BR (1) | BR112017026417B1 (ja) |
ES (1) | ES2730088T3 (ja) |
HU (1) | HUE044731T2 (ja) |
MX (1) | MX2017016028A (ja) |
PL (1) | PL3307293T3 (ja) |
PT (1) | PT3307293T (ja) |
TR (1) | TR201908938T4 (ja) |
WO (1) | WO2016198943A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3103465A1 (en) * | 2015-06-10 | 2016-12-14 | Raman Mehta | Formulations for the treatment of mucosal lesions |
KR102224051B1 (ko) * | 2019-04-04 | 2021-03-09 | 한국 한의학 연구원 | 건강 추출물을 유효성분으로 포함하는 중화항체 생성율 증진용 조성물 |
IT202000018949A1 (it) | 2020-08-03 | 2022-02-03 | Arterra Bioscience S P A | Estratto derivato da bucce di punica granatum per la prevenzione e il trattamento di infezioni virali |
IT202000026566A1 (it) * | 2020-11-06 | 2022-05-06 | Herbal E Antioxidant Derivatives Srl Ed In Forma Abbreviata H&Ad Srl | Combinazioni di antivirali e antimicrobici naturali, loro uso e formulazioni che le contengono |
WO2023037299A1 (en) * | 2021-09-09 | 2023-03-16 | Integria Healthcare (Australia) Pty Limited | Anti-inflammatory compositions comprising ginger and turmeric |
TR2022000292A2 (tr) | 2022-01-11 | 2022-02-21 | Tuerkiye Bilimsel Veteknolojik Arastirma Kurumu | SARS-CoV-2 Virüsüne Karşı Koruyucu Pastil/Çiğneme Tableti Üretimi |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004537575A (ja) * | 2001-08-06 | 2004-12-16 | ザ キグリー コーポレーション | 栄養補助剤およびそれらの使用方法 |
JP2007153888A (ja) * | 2005-11-14 | 2007-06-21 | Kanebo Foods Ltd | 体内浄化用組成物、それを用いた食品、入浴剤、化粧料、製剤及び有害金属排泄促進剤 |
US20090175971A1 (en) * | 2008-01-08 | 2009-07-09 | Mark Dreher | Method of using composition comprising pomegranate extracts against the common cold |
US20120107429A1 (en) * | 2009-07-08 | 2012-05-03 | Lee Woo-Song | Composition For The Prevention And Treatment Of Influenza Virus Infection And Composition For Suppressing Neuraminidase Activity Comprising Turmeric Extract |
JP2013001666A (ja) * | 2011-06-14 | 2013-01-07 | Yasuharu Omura | 栄養剤組成物 |
JP2013539770A (ja) * | 2010-10-11 | 2013-10-28 | インデナ エッセ ピ ア | 上気道の障害の治療用の製剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE202009002126U1 (de) * | 2009-02-13 | 2009-04-16 | Orthomol Pharmazeutische Vertriebs Gmbh | Spurenelement enthaltende Zusammensetzung |
WO2011068812A1 (en) * | 2009-12-04 | 2011-06-09 | Colgate-Palmolive Company | Oral compositions containing a combination of natural extracts and related methods |
CN102670588B (zh) | 2012-05-04 | 2013-11-20 | 中国科学院上海生命科学研究院湖州营养与健康产业创新中心 | 鞣花酸用于制备抗病毒药物的应用 |
CN103638502B (zh) | 2013-12-12 | 2015-07-01 | 苏振华 | 一种治疗白塞病的药物及其制备方法 |
CN104524508A (zh) | 2014-12-24 | 2015-04-22 | 赵红 | 一种治疗消化性溃疡的中药及其制备方法 |
-
2015
- 2015-06-10 EP EP15171354.2A patent/EP3103464A1/en not_active Withdrawn
-
2016
- 2016-06-10 JP JP2018516646A patent/JP6966998B2/ja active Active
- 2016-06-10 US US15/735,361 patent/US10758587B2/en active Active
- 2016-06-10 PL PL16732747T patent/PL3307293T3/pl unknown
- 2016-06-10 AU AU2016276145A patent/AU2016276145B2/en active Active
- 2016-06-10 CN CN201680032969.4A patent/CN108040468B/zh active Active
- 2016-06-10 HU HUE16732747 patent/HUE044731T2/hu unknown
- 2016-06-10 TR TR2019/08938T patent/TR201908938T4/tr unknown
- 2016-06-10 EP EP16732747.7A patent/EP3307293B1/en active Active
- 2016-06-10 ES ES16732747T patent/ES2730088T3/es active Active
- 2016-06-10 KR KR1020177037808A patent/KR20180030970A/ko not_active Application Discontinuation
- 2016-06-10 MX MX2017016028A patent/MX2017016028A/es unknown
- 2016-06-10 WO PCT/IB2016/000795 patent/WO2016198943A1/en active Application Filing
- 2016-06-10 BR BR112017026417-0A patent/BR112017026417B1/pt active IP Right Grant
- 2016-06-10 PT PT16732747T patent/PT3307293T/pt unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004537575A (ja) * | 2001-08-06 | 2004-12-16 | ザ キグリー コーポレーション | 栄養補助剤およびそれらの使用方法 |
JP2007153888A (ja) * | 2005-11-14 | 2007-06-21 | Kanebo Foods Ltd | 体内浄化用組成物、それを用いた食品、入浴剤、化粧料、製剤及び有害金属排泄促進剤 |
US20090175971A1 (en) * | 2008-01-08 | 2009-07-09 | Mark Dreher | Method of using composition comprising pomegranate extracts against the common cold |
US20120107429A1 (en) * | 2009-07-08 | 2012-05-03 | Lee Woo-Song | Composition For The Prevention And Treatment Of Influenza Virus Infection And Composition For Suppressing Neuraminidase Activity Comprising Turmeric Extract |
JP2013539770A (ja) * | 2010-10-11 | 2013-10-28 | インデナ エッセ ピ ア | 上気道の障害の治療用の製剤 |
JP2013001666A (ja) * | 2011-06-14 | 2013-01-07 | Yasuharu Omura | 栄養剤組成物 |
Non-Patent Citations (1)
Title |
---|
BIOMED RESEARCH INTERNATIONAL, vol. 2014, JPN6020006508, 2014, pages 186864 - 1, ISSN: 0004536883 * |
Also Published As
Publication number | Publication date |
---|---|
TR201908938T4 (tr) | 2019-07-22 |
EP3307293B1 (en) | 2019-03-20 |
JP6966998B2 (ja) | 2021-11-17 |
PL3307293T3 (pl) | 2019-11-29 |
AU2016276145A1 (en) | 2017-12-21 |
WO2016198943A1 (en) | 2016-12-15 |
HUE044731T2 (hu) | 2019-11-28 |
EP3307293A1 (en) | 2018-04-18 |
AU2016276145B2 (en) | 2022-05-26 |
MX2017016028A (es) | 2018-04-13 |
ES2730088T3 (es) | 2019-11-08 |
KR20180030970A (ko) | 2018-03-27 |
CN108040468A (zh) | 2018-05-15 |
EP3103464A1 (en) | 2016-12-14 |
US20180169175A1 (en) | 2018-06-21 |
PT3307293T (pt) | 2019-06-12 |
CN108040468B (zh) | 2021-08-20 |
BR112017026417B1 (pt) | 2021-04-27 |
US10758587B2 (en) | 2020-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6966998B2 (ja) | 口腔、咽喉及び気道の障害の治療のための配合物 | |
AlShuwayeb et al. | Molecular and chemical therapeutic features of Urtica species | |
US20160000826A1 (en) | Gargle Method to Reduce the Duration of Common Cold Symptoms | |
US20170020946A1 (en) | Analgesic compositions and methods of use | |
CN108012530B (zh) | 用于治疗粘膜损伤的制剂 | |
US20210308071A1 (en) | Treatment method to abort and or reduce the severity of upper respiratory viral illness as well as to prevent upper respiratory viral illness in humans | |
JP2006206461A (ja) | アレルギー疾患の予防・治療用組成物 | |
JP7465587B2 (ja) | Covid-19および関連する疾患の管理のための組成物 | |
Suriyan et al. | A randomized clinical study to evaluate the efficacy and safety of OUTBREAK in mild and moderate COVID19 positive patients | |
Ahmed et al. | EVALUATING CLINICAL EFFICACY OF TULSI AEROSOL IN THE MANAGEMENT OF UPPER RESPIRATORY TRACT INFECTION WSR TO PRATISHYAY-A PILOT STUDY | |
Shelke et al. | An open label, randomized, multicenter, comparative, three arm Phase II clinical study to evaluate the safety and efficacy of mixture of five species of Ocimum in subjects with acute common cold | |
DE102004063363A1 (de) | Capsaicin-haltige Arzneien zur Behandlung von Bronchial-Infekten und Allergien | |
AU2016100033A4 (en) | Biopharmaceutical with antiviral activity. | |
IT202000026566A1 (it) | Combinazioni di antivirali e antimicrobici naturali, loro uso e formulazioni che le contengono | |
Kadawla et al. | Investigating the Synergistic In-vitro Anti-inflammatory Potentials of Standardized Fruit Extract of Eugenia jambolana and Standardized Fruit Extract Piper nigrum Combinations | |
Achudume et al. | Effects of the extracts of Pycanthusangolensis against chemically induced acute hepatotoxicity | |
Saleman et al. | Antihelicobacter pylori activity by powdered of Ginger, Pomegranates, Arabic gum and Curcuma mixed with honey | |
WO2011124493A1 (de) | Zusammensetzung enthaltend bestandteile aus sonnenhut, holunder und kamille zur behandlung von erkältungskrankheiten | |
WO2022123605A1 (en) | Herbal composition for covid 19 treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20180115 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20180518 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190415 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200225 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200221 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200601 |
|
A603 | Late request for extension of time limit during examination |
Free format text: JAPANESE INTERMEDIATE CODE: A603 Effective date: 20200601 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200722 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210319 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210706 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211005 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211019 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211022 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6966998 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |